18F-胆碱PET/CT代谢参数对接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者的预后价值
回顾性分析94例多西他赛治疗后接受阿比特龙(52例)或恩扎卢胺(42例)的转移性去势抵抗性前列腺癌患者,基线18F-胆碱PET/CT测量最多20个病灶的MTV、SUVmean、SUVmax和TLA总和。单因素分析中SMTV、SSUVmax、STLA均与PFS和OS显著相关,多因素分析中仅STLA对PFS和OS保持显著(P<0.0001和P=0.001)。
要点
- 基线18F-胆碱PET/CT的SMTV、SSUVmax、STLA在单因素分析中均与PFS和OS显著相关。
- 多因素分析中仅STLA对PFS和OS保持独立预后意义(P<0.0001和P=0.001)。
- 基线PSA对OS保持一定可靠性(P=0.034)。
核心结论
- 18F-胆碱PET/CT的半定量参数在接受阿比特龙或恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者中具有预后作用。
研究设计与样本
- 回顾性研究纳入94例多西他赛治疗后接受阿比特龙(n=52)或恩扎卢胺(n=42)的转移性去势抵抗性前列腺癌患者,平均年龄74岁(范围42-90岁)。
- 基线行18F-胆碱PET/CT,测量每个病灶的MTV、SUVmean、SUVmax和TLA,并分析最多20个病灶的SMTV、SSUVmean、SSUVmax和STLA总和。
- 每月评估血清PSA反应,每3个月评估影像学反应;采用单因素分析将这些数据与PFS和OS相关。
主要发现
- 中位SMTV为130 cm3,中位SSUVmax为106.5,中位STLA为495,070。
- 单因素分析中SMTV、SSUVmax和STLA均与PFS和OS显著相关。
- 多因素分析校正病灶和年龄后,仅STLA对PFS和OS显著(P<0.0001和P=0.001)。
- 基线PSA对OS保持一定可靠性(P=0.034)。
关键数值与推荐
- MTV定义为固定阈值40% SUVmax内所有空间相连体素组成的感兴趣体积。
- TLA定义为MTV与平均标准化摄取值(SUVmean)的乘积。
- 分析最多20个病灶的SMTV、SSUVmean、SSUVmax和STLA总和值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of 18F-choline positron emission tomography/computed tomography (FCH-PET/CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) has been firmly established in recent years. We analyzed the prognostic value of functional parameters such as mean standardized uptake volume (SUVmean), maximum standardized uptake volume (SUVmax), metabolic total volume (MTV; the volume of interest consisting of all spatially connected voxels within a fixed threshold of 40% of the SUVmax), and total lesion activity (TLA: the product of MTV and mean standardized uptake value) estimated with FCH-PET/CT in mCRPC patients in progression after docetaxel and treated with new antiandrogen receptor therapies, abiraterone or enzalutamide. METHODS: We retrospectively studied 94 mCRPC patients, mean age 74 years (range 42-90), previously treated with docetaxel who were treated with either abiraterone (n = 52) or enzalutamide (n = 42). An FCH-PET/CT was performed at baseline, and patients were evaluated on a monthly basis for serological PSA response and every 3 months for radiological response. We measured MTV, SUVmean, SUVmax and TLA for each lesion and analyzed the sum of MTV (SMTV), SUVmean (SSUVmean), SUVmax (SSUVmax) and TLA (STLA) values for a maximum of 20 lesions. Univariate analysis was used to correlate these data with PFS and OS. RESULTS: We observed a median SMTV of 130 cm3, median SSUVmax of 106.5 and a median STLA of 495,070. All of these parameters were significant for PFS and OS in univariate analysis, while only STLA was significant for PFS and OS in multivariate analysis after adjusting for lesion and age (p < 0.0001 and p = 0.001, respectively). Baseline PSA values maintained a certain reliability for OS (p = 0.034). CONCLUSIONS: Semiquantitative parameters of FCH-PET/CT play a prognostic role in mCRCP patients treated with abiraterone or enzalutamide.
引用
- Caroli P, De Giorgi U, Scarpi E, et al. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Eur J Nucl Med Mol Imaging. 2017. PMID: 29110067. doi:10.1007/s00259-017-3866-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。